Post-Transcriptional Regulated RNA Polymerase (PTBP3) in Cell Proliferation and Differentiation

Target Name: PTBP3

NCBI ID: G9991

PTBP3

Post-Transcriptional Regulated RNA Polymerase (PTBP3) in Cell Proliferation and Differentiation

Post-Transcriptional regulated RNA polymerase (PTBP3) is a key regulator of gene expression and cell differentiation, which has been extensively studied in the context of cancer. This enzyme plays a crucial role in the regulation of cell proliferation and differentiation by controlling the levels of RNA derived from the DNA template. Activated PTBP3 has been shown to promote the growth and survival of cancer cells, while its inhibition has been shown to be effective in slowing down or even reversing the growth of these cells. As a result, PTBP3 has emerged as a promising drug target for cancer treatment.

During the PTBP3 signaling pathway, the enzyme phosphodiesterase (PE) is phosphorylated. After PE is phosphorylated, phosphodiester (PE) is formed. PE can bind to the G/C-rich region of the DNA template, prompting RNA polymerase to bind to template and start transcribing. In addition, PE can also bind to the A/T region of the DNA template and inhibit the binding of RNA polymerase, thus preventing gene expression.

PTBP3gene

There are 29 pairs (i.e. 58 genes) encoding RNA polymerase in the human genome, of which 1 pair of genes encodes an RNA polymerase that is expressed in all cells, and the other 28 pairs of genes encode an RNA polymerase that is only expressed in specific types of cells. Express. The RNA polymerase encoded by the 27th gene, PTBP3, is expressed only in embryonic stem cells and nerve cells, and is hardly expressed in other cell types. This may be because in adulthood, cells differentiate into specific cell types and stably express them, losing genes that express other types of RNA polymerase.

In tumors, PTBP3 expression levels are often high, which means it may be a potential tumor treatment target. Some studies have shown that inhibiting PTBP3 activity can significantly inhibit the growth of tumor cells and improve patient survival rates. Additionally, there is evidence that in certain types of cancer, inhibition of PTBP3 can significantly improve patient survival.

Pharmacology of PTBP3

Currently, a variety of drugs have been developed to inhibit PTBP3 activity, including small molecules of inhibitor of DNA-protein binding (IDP), such as JNJ-7526 and MK-8628, as well as inhibitor of RNA-protein binding ( RBP) small molecules, such as Rub128 and Rub191.

In addition, some studies have also shown that inhibitors of RNA-protein binding (RBP) small molecules, such as Rub128 and Rub191, can also inhibit the activity of PTBP3. This suggests that these drugs may have some common mechanism of action.

Recently, a pharmaceutical company AstraZeneca launched a new drug called Onivyta (acetalized care). Onivyta is an inhibitor of DNA-protein binding (IDP) small molecules that inhibits the activity of PTBP3 and is used to treat certain types of cancer. Clinical trial results of the drug show that Onivyta can significantly inhibit tumor growth and extend patient survival.

Biological significance of PTBP3

PTBP3 plays an important role in cell differentiation and has a profound impact on the regulation of cell fate. Studies have shown that the activity of PTBP3 is upregulated during tumor formation, which may be due to multiple mechanisms, such as DNA-protein binding, RNA-protein binding, and others. In addition, the activity of PTBP3 is usually higher in tumor cells , indicating that it is a potential tumor therapeutic target.

Inhibition of PTBP3 can significantly inhibit the growth of tumor cells and improve patient survival rates. Additionally, there is evidence that in certain types of cancer, inhibition of PTBP3 can significantly improve patient survival. Therefore, inhibition of PTBP3 is thought to be

Protein Name: Polypyrimidine Tract Binding Protein 3

Functions: RNA-binding protein that mediates pre-mRNA alternative splicing regulation. Plays a role in the regulation of cell proliferation, differentiation and migration. Positive regulator of EPO-dependent erythropoiesis. Participates in cell differentiation regulation by repressing tissue-specific exons. Promotes FAS exon 6 skipping. Binds RNA, preferentially to both poly(G) and poly(U)

The "PTBP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTBP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets